Treatment with anti-VEGF therapy results in rapid improvements in anatomy and function in patients with macular edema caused by branch retinal vein occlusion. Medscape Medical News
Uncategorized
Phase 2 study initiated for oral anti-VEGF, anti-PDGF inhibitor
MIAMI — An oral tyrosine kinase inhibitor under study for use in treating wet age-related macular degeneration has moved forward into a phase 2 trial, a speaker said.Reporting positive phase 1 study results for X-82 (Xcovery Vision), an inhibitor of both anti-VEGF and anti-PDGF activity, Jason S. Slakter, MD, said at Angiogenesis, Exudation, and Degeneration 2015, “[X-82] has low toxicity in oral administration. Phase 1 study has shown some anatomic benefit, and a phase 2 program is kicking off.”
Roche announces acquisition of Signature Diagnostics
Roche announced today the acquisition of Signature Diagnostics AG, a privately held company based in Potsdam, Germany. Signature is a translational oncology and genomics company that develops large blood plasma and tissue biobanks in multiple cancers, …
Uncategorized
VIDEO: Range of MIGS devices in development continues to expand
SAN FRANCISCO – At Glaucoma 360, Thomas W. Samuelson, MD, discusses the nine companies presenting different micro-incisional and micro-invasive glaucoma devices this year, exemplifying the growth in the burgeoning sector of glaucoma surgery.
Uncategorized
Phase 3 studies of lampalizumab for geographic atrophy enrolling
MIAMI — Phase 3 studies of lampalizumab are underway based on results of the phase 2 MAHALO study, which showed evidence that treatment slows the rate of geographic atrophy progression in patients with age-related macular degeneration, a speaker told colleagues.“Certainly there is a significant unmet medical need with regard to geographic atrophy,” Carl D. Regillo, MD, said at Angiogenesis, Exudation, and Degeneration 2015. “There’s more than 5 million people worldwide affected by GA, and there’s no effective treatment.”
Uncategorized
AMD patients with low luminance vision garner twice the benefit of Lucentis treatment
MIAMI — Vision in dim light improves twice as much as vision in normal light with Lucentis therapy in patients with age-related macular degeneration, Ronald E. Frenkel, MD, FACS, told colleagues at Angiogenesis, Exudation, and Degeneration 2015.“The gap between normal and dim vision at baseline may predict the patient’s response to treatment,” Frenkel said. “A smaller gap may be a manifestation of more mild retinal disease, and a wider gap portends poor vision gains.”